Form 4: Quaker Chemical Exec's Equity Transactions

An executive at Quaker Chemical Corp. reported significant equity transactions, including vesting of performance and restricted stock units, and a new RSU grant.

Summary

• Jeewat Bijlani, EVP, Global Specialties & Chief Growth Officer of Quaker Chemical Corp. (KWR), reported multiple equity transactions on March 15, 2026.
• Bijlani earned 1,297 shares of common stock from the vesting and settlement of Performance Stock Units (PSUs) awarded on March 15, 2023, based on achieving adjusted return on invested capital (ROIC) metrics over a three-year period.
• A total of 1,536 shares (433, 429, and 674 shares) were acquired through the conversion of Restricted Stock Units (RSUs) into common stock.
• An additional 32 shares were acquired from the settlement of Dividend Equivalent Rights (DERs) accrued on RSU grants from March 15, 2024, and March 15, 2025.
• Bijlani disposed of 923 shares of common stock at a price of $118.45 per share to satisfy tax withholding obligations related to the vesting of restricted stock, PSUs, and RSUs.
• A new grant of 2,195 time-based Restricted Stock Units (RSUs) was received, which will vest in three annual installments beginning on March 15, 2027.
• Following these transactions, Bijlani directly beneficially owns 6,748 shares of common stock and indirectly owns 61 shares through a 401(k) plan as of December 31, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing routine executive compensation activities and compliance with disclosure requirements rather than a significant operational or financial announcement.

Positives

• The vesting of 1,297 Performance Stock Units (PSUs) indicates the achievement of adjusted return on invested capital (ROIC) metrics over the three-year performance period, reflecting successful execution of company goals.
• The grant of 2,195 new time-based Restricted Stock Units (RSUs) demonstrates continued long-term incentive alignment between the executive and shareholder interests.

Negatives

• 923 shares of common stock were surrendered to satisfy tax withholding obligations, representing a disposition of shares by the executive.

Future Outlook

The executive has a new grant of 2,195 time-based Restricted Stock Units (RSUs) that will vest in three annual installments beginning on March 15, 2027, indicating future equity compensation tied to continued employment.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for publicly traded companies, detailing changes in beneficial ownership by insiders. These transactions, primarily related to executive compensation through equity awards, are standard practice for incentivizing management and aligning their interests with shareholders.

Stakeholder Impact

• Shareholders: The transactions reflect standard executive compensation practices, aligning executive incentives with company performance and long-term value creation. The disposition of shares for tax purposes is a common occurrence and does not necessarily indicate a change in confidence.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The remaining installments of the 2024 RSU grants will continue to vest annually.
• The remaining installments of the 2025 RSU grant will continue to vest annually.
• The newly granted 2,195 time-based RSUs will begin vesting in three annual installments starting March 15, 2027.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events, including the vesting of performance and restricted stock units and a new RSU grant, along with shares disposed for tax withholding. Such transactions are standard for insider compensation and generally do not provide new material information that would significantly alter the investment thesis for Quaker Chemical Corp. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason for a 'buy' or 'sell' decision.

Keywords

KWR, Quaker Chemical, Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, Performance Stock Units, Dividend Equivalent Rights, Equity Vesting